Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A single‑center retrospective study of 988 unrelated donor HCTs with PTCy found no significant differences in survival or relapse for isolated HLA‑DQB1 mismatch, 7/8 mismatches, or older donor age; 7/8 mismatch increased severe acute GVHD a
A CIBMTR registry cohort (n=10,025) found donor age predicted worse overall survival with conventional calcineurin inhibitor prophylaxis but not with posttransplant cyclophosphamide (PTCy); attenuation was driven by reduced nonrelapse morta
A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI
A single-center study developed and internally validated a 48‑hour post‑liver transplant AKI risk model using five readily available preoperative and intraoperative variables (HE, alcohol cirrhosis, ALBI ≥ −1.78, operation time ≥560 min, an
Deceased donor kidney transplantation improves survival compared to dialysis waitlisting, with benefits varying by donor kidney quality and recipient age. Low-risk kidneys yield the greatest survival gains, particularly in older recipients.
The International Xenotransplantation Association (IXA) 2025 position paper offers evidence-based recommendations for initial clinical trials of genetically engineered porcine kidney transplants for end-stage renal disease, focusing on dono
Combining liver transplant with sleeve gastrectomy yields sustained weight loss, improved metabolic syndrome, and reduced liver allograft steatosis, without increasing mortality or graft loss, offering an effective treatment for obese patie
This article reviews recent studies on EBV transmission in pediatric kidney transplants, highlighting risk factors, monitoring strategies, and implications for reducing posttransplant lymphoproliferative disorder (PTLD).
This systematic review and meta-analysis evaluate cancer and graft outcomes in transplant recipients treated with immune checkpoint inhibitors, revealing differences by cancer type and potential strategies to reduce rejection risk.
This article explores the clinical features, underlying mechanisms, and potential therapeutic targets for chronic rejection in VCA, emphasizing the importance of tailored interventions to improve long-term graft survival.
Recent advances in genetically modified pig-to-human organ transplantation offer promising solutions for acute liver failure, bridging critical gaps in organ availability and raising important ethical and regulatory considerations.
This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney f
This article reviews microsurgical techniques and patient outcomes in penile replantation, highlighting complications, innovative management strategies, and the critical need for standardized protocols to improve functional and aesthetic re
Since the landmark combined liver–kidney transplant in 1984, advances in surgical techniques, immunosuppression, and donor allocation have revolutionized care for patients with dual organ failure. Emerging innovations, including gene-edited
The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.
Zimislecel, an allogeneic stem cell-derived islet-cell therapy, demonstrates promising safety and efficacy for type 1 diabetes, restoring physiologic islet function and enabling insulin independence in a phase 1-2 trial.
This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality with
Inpatient palliative care during hematopoietic stem cell transplantation improves patients’ quality of life, reduces depression and PTSD symptoms, and offers sustained psychological benefits up to six months post-transplant.
Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for
Fecal microbiota transplantation (FMT) shows promise in improving gastrointestinal and behavioral symptoms in children with autism spectrum disorder (ASD), but further rigorous trials are needed to confirm its efficacy and optimize protocol
Open language-specific specialty feeds and department pages.